SEC Form 4 · accession 0001683168-26-007398
Valion Bio, Inc. · VBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dean Zikria
Officer — Interim CEO · Director
Period of report
Sep 22, 2026
Accepted (ET)
Sep 24, 2026 · 4:46 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001787740
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F1,F2 | — | Sep 22, 2026 | A | 50,000 | A | — | — | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1Each Restricted Stock Unit is convertible into one share of Common Stock.
- F2One fourth (1/4) of the Restricted Stock Units shall vest quarterly, with the first vesting occurring on December 22, 2026.
- F3These numbers have been adjusted to reflect the reverse stock split of the common stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026.